类风湿关节炎患者甲氨蝶呤治疗第一年疾病感知的变化
基于英国多中心队列RAMS(N=1087),描述RA患者起始MTX治疗后一年内疾病感知的轨迹及其与结局的关联。潜类别增长模型识别出积极感知组(N=322)、消极感知组(N=534)和改善组(N=231)三个亚组;消极感知组随访期间残疾、疼痛和疲劳更差,基线残疾与其他PROs与分组相关。
要点
- RA患者起始MTX第一年内疾病感知可分为积极、消极和改善三个轨迹亚组。
- 消极疾病感知组随访期间残疾、疼痛和疲劳结局更差,且控制炎症后仍成立。
- 基线残疾及其他PROs与疾病感知轨迹分组相关,疾病感知或为可干预靶点。
核心结论
- 消极疾病感知与RA患者随访期间较差的患者报告结局相关。
- 改善组表明RA患者的疾病感知在治疗第一年内可以发生变化。
- 疾病感知是潜在治疗靶点,需通过随机试验评估干预效果。
研究设计与样本
- 数据来自英国多中心队列研究RAMS,纳入首次起始MTX治疗的RA患者。
- 在基线、6个月和12个月进行评估,分析人群N=1087。
- 使用潜类别增长模型识别B-IPQ八个条目轨迹相似的亚组,并以多项逻辑回归和线性混合模型分析。
主要发现
- 识别出三个亚组:积极疾病感知组(N=322)、消极疾病感知组(N=534)和改善组(N=231)。
- 改善组在随访期间从消极疾病感知转为积极疾病感知。
- 基线残疾与分组相关:积极 vs 消极 RRR 0.37(95% CI 0.25, 0.54);改善 vs 消极 RRR 0.60(95% CI 0.43, 0.83)。
- 其他PROs(疼痛、疲劳、焦虑、抑郁)也与分组相关。
- 控制炎症后,消极组随访期间残疾、疼痛和疲劳仍比其他组更差。
关键数值与推荐
- B-IPQ用于评估疾病感知,炎症评分采用2组分DAS28计算。
- 基线残疾与积极 vs 消极组的RRR为0.37(95% CI 0.25, 0.54),改善 vs 消极组为0.60(95% CI 0.43, 0.83)。
临床怎么用
- 在RA患者起始MTX治疗时评估疾病感知,识别消极感知或可改善的患者。
- 对消极疾病感知患者可考虑心理或教育干预,但需随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the illness perceptions of patients with RA over the first year of MTX treatment, and the association between illness perceptions and outcomes. METHODS: Data came from the Rheumatoid Arthritis Medication Study (RAMS), a UK multicentre cohort study of RA patients starting MTX for the first time. Patients were assessed at baseline, and at 6 and 12 months. Patients completed the Brief Illness Perception Questionnaire (B-IPQ) at each assessment, as well as other patient-reported outcomes (PROs). The inflammation score (2-component DAS28) was calculated. Subgroups of patients with similar trajectories across the eight (B-IPQ) items were identified using a latent class growth model. Predictors of group membership were identified using multinomial logistic regression. Associations between subgroups and PROs over follow-up were assessed using linear mixed models. RESULTS: Three subgroups were identified in the analysis population (N = 1087): Positive illness perceptions (N = 322), Negative illness perceptions (N = 534) and Improvers (N = 231) who switched from negative to positive illness perceptions over follow-up. Baseline disability was associated with group membership [Positive vs Negative: relative risk ratio (RRR) 0.37, 95% CI: 0.25, 0.54; Improvers vs Negative: RRR 0.60, 95% CI: 0.43, 0.83], as were other PROs (pain, fatigue, anxiety, depression). The Negative group had worse disability, pain and fatigue over follow-up compared with the other groups, controlling for inflammation. CONCLUSION: Negative illness perceptions are associated with poor PROs over time. The Improvers subgroup illustrated that illness perceptions can change in RA. Illness perceptions represent a potential therapeutic target that should be assessed using randomized trials.
引用
- Gwinnutt JM, Norton S, Hyrich KL, et al. Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy. Rheumatology (Oxford). 2021. PMID: 33188696. doi:10.1093/rheumatology/keaa615
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。